Merck places children’s HIV drug in shared non-profit patent pool

U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap paediatric formulations for use in poor countries.

The non-profit Medicines Patent Pool (MPP), which aims to persuade leading drug companies to share rights to their products with generic manufacturers, said on Tuesday the deal for Merck’s raltegravir would add to the treatment arsenal.

Read also: OIS strengthens commitment to mould globally competitive students

Merck has not previously participated in the scheme. The MPP has signed deals with Bristol-Myers Squibb, Gilead Sciences, Roche and ViiV Healthcare, which is majority-owned by GlaxoSmithKline.

Two months ago, MPP signed a licence with AbbVie for paediatric versions of two other HIV drugs, lopinavir and ritonavir.

The licensing agreement with Merck means other companies can use raltegravir in paediatric medicines sold in low- and middle-income countries where 98 percent of children with HIV live.